Navigate the Complexities of Market Access and HEOR
Don’t just react to a changing market, lead it. ADVI drives life science commercialization by providing a clear, data-driven foundation that connects government policy, clinical proof, and patient access to ensure your innovation reaches its full potential.
In an era of shifting mandates, certainty is your greatest asset.
Most consulting firms are reactive, you call them only when a crisis hits. ADVI work differently. As your long-term strategic partner, ADVI provide the foresight to navigate obstacles before they appear. We anticipate how today’s news shapes tomorrow’s policies, translating complex data into the actionable insights you need to make confident decisions through implementation and beyond.
At ADVI, we don’t just monitor the shifting landscape of healthcare policy—we help our clients navigate it. Whether it is leveraging HEOR data to prove asset value, modeling the impact of the Inflation Reduction Act, or securing strategic market access for a breakthrough therapy, our mission is to turn regulatory complexity into a clear, actionable path toward commercial success and patient impact. We help our clients obtain codes, secure reimbursement, and gain or enhance coverage. – Marc Samuels, JD, MPH, Chief Executive Officer
Policy analytics (retrospective, including “MFP in Action” tracking)
Access and reimbursement landscape assessment
Gross-to-Net (GTN) impact modeling
Commercialization and market access roadmap
Pricing and contracting
340B, ASP, and WAC modeling
Value proposition strategy and message testing
IRA negotiation strategy for targeted and competing products
IRA COVID analysis (i.e., IRA negotiation target list)
Patient access journey with claims data peri-launch
Formulary analyses
Customer segmentation and targeting
Competitive simulations
Future scenario planning (e.g., FutureScape)
CEO and executive-level organizational strategy and design (i.e., GAPP-focused)
Risk mitigation strategy
Portfolio planning
Launch sequencing (e.g., pricing adaptation to shifting market conditions like IRA and MFN)
CMS, MAC, and MolDx strategy and engagement
Coverage and benefit category strategy
Coding and payment strategy (inpatient and outpatient)
Coding and payment application and submission: CPT, HCPCS, DRG/NTAP, ICD-10
Physician payment (RUC valuation for CPT/payment changes for Medicare CLFS, OPPS and IPPS
Payer, policymaker and provider engagement strategy and support (including Ad Boards)
Evidence gap assessment
Field team access and reimbursement training
Commercial analytics launch support
Product uptake and market share
Account segmentation
Physician prescribing and billing patterns
Patient switching and adherence
Claims analysis
State fiscal notes
Rules-based modeling
Policy impact modeling:
Part D Liability
Part B Wastage
IRA analytics (i.e., MFP estimation)
Forecast modeling
HEOR Capabilities
Systematic reviews and target literature searches
Elicitation and value of information
Delphi Panels
Cost of illness and burden of disease studies
Indirect treatment comparisons, survival analyses, and extrapolations
Mapping data crosswalks and conducting within-trial, patient-level data analyses
PICOs prediction and JCA planning
Cost-effectiveness models
Budget impact models
Model strategy and design
Model testing and validation
Simulation modeling
Exportable leave-behind reports
ICER-LITE models
Revenue models
Model adaptations
Healthcare economic information
Key value message and value proposition development
Conference proceedings and publications
Salesforce effectiveness materials
Stakeholder communication tools and aids
Global value dossiers
Value story decks
Real-world evidence (RWE) strategy
Evidence gap analysis and RWE study tactical recommendation
RWE feasibility and study design
Patient level data analysis
Evidence synthesis
Scientific communications
RCT cross over and bridge study design
ICER strategy and advocacy
ICER report development, in whole or part
US and global pricing ethos, pricing methodology development and payer advocacy
HTA and reimbursement submissions to NICE or other global bodies in partnership with advisors
HTA (NICE) scientific advice
Mock HTA panels
Evidence package critical appraisals with advisors
Specialized Expertise
Real-Time Data to Power Your Market Access Strategy with CMS VRDC Analytics
Partner with ADVI to back your HEOR initiatives and life science commercialization strategies with the industry’s most robust healthcare data. Through the CMS Virtual Research Data Center (VRDC), ADVI can offer near-real-time access to 100% Medicare Fee-for-Service (Parts A, B, and D) and Medicare Advantage data. With newly expanded access to 100% Medicaid and Managed Medicaid across all 50 states, we turn raw longitudinal claims into actionable evidence.
Leading the Way in Cell and Gene Therapy Access Models
Cell and Gene therapies require more than traditional strategies. We act as your health economics consulting firm, developing innovative payment models and long-term market access support for high-cost, high-impact curative therapies.
Is Your Portfolio Ready for the Inflation Reduction Act (IRA)?
Our consultants, specializing in the Inflation Reduction Act and Most Favored Nation, provide rigorous impact modeling and strategic advisory to mitigate risk and protect innovation value.
Driving Expert Consensus for High-Stakes HEOR Strategy with Delphi Panels
ADVI leverages the validated RAND/UCLA Modified Delphi methodology to build clear, credible clinical guidance that drives expert consensus, informs commercialization, and secures a powerful foundation for market access.
Ready to Get Started?
To learn more about our work, contact us at innovate@advi.com or fill out the form below. ADVI offers expert advice and influential solutions, informed by data and guided by a clear vision of the complex intersection of life sciences/healthcare innovation, economics, policy, and patient impact.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.
